Clinical Trial Update: Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the efficacy and safety of MP-424 in combination with peginterferon alfa-2b and ribavirin in adults with chronic hepatitis C who di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MP-424
• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2012-08-20